伊马替尼在胃肠间质瘤中的应用

Clinicalapplication of imatinibin gastrointestinal stromal tumor

目前,伊马替尼等酪氨酸激酶受体抑制剂,对转移/复发胃肠间质瘤(gastrointeseinal stromal tumors,GIST)的治疗呈现出显著疗效。同时,高危GIST术前新辅助治疗的减瘤效应,无论是在提高手术切除率及安全性方面,还是从器官保留角度来看,都起到了至关重要的作用。但术前伊马替尼治疗改善生存的作用还未得到充分证实,最佳术前及术后药物治疗时间仍未得到最终解决;文章旨在阐述近年来伊马替尼在GIST中的应用方面的研究进展。

Tyrosine kinase inhibitor imatinib mesylate is effective for metastasis/recurrent gastrointestinal stromal tumors(GISTs).Likewise,imatinib would be effective in the neoadjuvant therapy for high-risk GIST.Neoadjuvanttherapy may have the potential to increase the complete resection rate and to avoid the surgical rupture by decreasing the tumor size.Neoadjuvant therapy is alsoexpected to be favored from the viewpoint of organ/function preservation by tumorshrinkage.However,proof of the survival effectiveness of neoadjuvant imatinib therapy has not been sufficiently demonstrated.Clinicalquestions still remain about the most appropriate period of pre-and post-operative imatinib administration.The aim of this article is to elucidate the research progress regarding the application ofimatinibin therapy for GIST.